Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | STIM1 | Q13586 | 5/20 | 0.61 |
| ▸ | ORAI1 | Q96D31 | 5/20 | 0.61 |
| ▸ | BDKRB1 | P46663 | 12/20 | 0.40 |
| ▸ | PFKFB3 | Q16875 | 1/20 | 0.39 |
| ▸ | NPC1 | O15118 | 1/20 | 0.39 |
| ▸ | PKM | P14618 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14225965 | 0.88 | STIM1 (0.53) | STIM1ORAI1BDKRB1NPC1PKM | |
| SCHEMBL14225966 | 0.84 | STIM1 (0.57) | STIM1ORAI1BDKRB1PFKFB3 | |
| SCHEMBL14225942 | 0.82 | STIM1 (0.79) | STIM1ORAI1BDKRB1 | |
| SCHEMBL14225936 | 0.81 | STIM1 (0.79) | STIM1ORAI1BDKRB1PFKFB3NPC1 | |
| SCHEMBL14226014 | 0.81 | STIM1 (0.79) | STIM1ORAI1BDKRB1PFKFB3 | |
| SCHEMBL12156303 | 0.78 | NPC1 (0.58) | STIM1ORAI1NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL14225895 | 0.77 | STIM1 (0.51) | STIM1ORAI1BDKRB1PFKFB3SMN1; SMN2 | |
| SCHEMBL12156304 | 0.77 | IL2 (0.56) | STIM1ORAI1NPC1PKMRAB9A | |
| SCHEMBL14225993 | 0.76 | STIM1 (1.00) | STIM1ORAI1BDKRB1 | |
| SCHEMBL12156307 | 0.74 | ABL1 (0.53) | STIM1ORAI1NPC1RAB9ASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120316182-A1 | COMPOUNDS THAT MODULATE INTRACELLULAR CALCIUM | CALCIMEDICA, INC. (US) | 2012-12-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120316182-A1 | COMPOUNDS THAT MODULATE INTRACELLULAR CALCIUM | ORAI1, SARAF, RYR2 | STIM1 17/4885ORAI1 1/4885BDKRB1 3376/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.